Breathe Well Live Well
|
Acton Pharmaceuticals, Inc. Announces Publication of AEROSPAN(R) (Flunisolide …
MarketWatch (press release) AEROSPAN Inhalation Aerosol is an orally inhaled corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older. In this double-blind, placebo-controlled study, … |
View full post on asthma – Google News
|
N30 Pharmaceuticals Announces Publication of S-Nitrosoglutathione Reductase …
Marketwire (press release) The report focuses on the lead chemical series which generated N30 N6022, a first in class GSNOR inhibitor currently in Phase 1b/2a trials for the treatment of asthma. GSNOR breaks down S-nitrosoglutathione (GSNO), and as such is an important regulator … |
View full post on asthma – Google News
|
Promedior Announces Publication Of New Research Demonstrating Pentraxin-2/SAP …
Medical News Today (press release) "Further investigation of the therapeutic effect of PTX-2/SAP in clinical asthma progression and exacerbation is a promising area for future research. … |
View full post on asthma – Google News
|
Promedior Announces Publication of New Research Demonstrating Pentraxin-2/SAP …
Bradenton Herald “Further investigation of the therapeutic effect of PTX-2/SAP in clinical asthma progression and exacerbation is a promising area for future research. … |
View full post on asthma – Google News